CDK9 and lymphoma: The CDK9 inhibitor AZD4573 was also found to indirectly down-regulate BFL-1 in conjunction with MCL-1 in BH3-mimetic–resistant lymphoma cell lines and lead to in vivo tumour regressions in BFL-1+ DLBCL PDX models [56].